Overview

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

Status:
RECRUITING

Trial end date:
2028-08-01

Target enrollment:

Participant gender:

Summary

This trial is a pilot-scale, single institution randomized, placebo-controlled trial to assess the feasibility, acceptability, and efficacy of administering dapagliflozin for cardiovascular risk reduction in the postpartum period. The target population is patients at high risk of adverse cardiovascular outcomes within five years post-delivery. Eligible participants will be randomized to receive either: 1) dapagliflozin (10mg daily) for six months (DAPA group) or 2) an orally administered, daily placebo (Control group). The study hypothesizes: The dapagliflozin group will have higher cardiovascular risk reduction scores than the Control Group.

Phase:

PHASE4

Details

Lead Sponsor:

University of Michigan

Collaborators:

American Association of Obstetricians and Gynecologists Foundation
Society for Maternal-Fetal Medicine Foundation

Treatments:

dapagliflozin